[Adjuvant chemotherapy in primary breast cancer].
Adjuvant chemotherapy reduces the relative risk of relapse by about 25%--independent of the nodal status. Anthracycline-containing regimens are considered standard for adjuvant chemotherapy. In single studies, superiority to CMF has only been shown for anthracycline-containing polychemotherapies with at least three substances or a sequential anthracycline-CMF therapy. Recent data show that adding taxanes to anthracycline-containing regimens may lead to significant survival advantages. Based on trial results published so far, taxanes are a valid adjuvant therapy option in node-positive breast cancer. In Germany, their optimal use is currently being evaluated in several clinical trials (i.e. NNBC-3, ECDoc, ADEBAR). Up-to-date evidence-based therapy recommendations for adjuvant chemotherapy can be found in the S2 guidelines of the working group on gynecological oncology (AGO) expert panel 'breast' (www.agoonline. de).
Harbeck
N
N
Frauenklinik, Klinikum rechts der Isar, Technischen Universität Munich. nadia.harbeck@lrz.tum.de
D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology; D009367:Neoplasm Staging; D015996:Survival Rate; D016896:Treatment Outcome
D018943:Anthracyclines